14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today AXSM ranks #18060 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Axsome Therapeutics Stock Forecast NASDAQ:AXSM

$28.52 (-5.50%)

Volume: 536k

Closed: Jan 19, 2022

Hollow Logo Score: -5.999

Axsome Therapeutics Stock Forecast

$28.52 (-5.50%)

Volume: 536k

Closed: Jan 19, 2022

Score Hollow Logo -5.999

Axsome Therapeutics Company Profile

25 Broadway

New York NY 10004



Industry: Biotechnology

Sector: Healthcare

Axsome Therapeutics


Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, develops therapies for the management and treatment of central nervous system disorders. Its product candidates include AXS-02, which is in Phase III trial for the treatment of complex regional pain syndrome, knee osteoarthritis, and chronic low back pain; and AXS-05 that is in Phase III trial for the treatment of resistant depression and agitation in patients with Alzheimer's disease. The company is also developing AXS-06 for the treatment of chronic pain disorders. Axsome Therapeutics, Inc. was founded in 2012 and is based in New York, New York.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE